Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose

@inproceedings{Hislop2012SystematicRO,
  title={Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose},
  author={Jennifer Hislop and Graham Mowatt and Pawana Sharma and Cynthia Fraser and A. I. Elders and David S. Jenkinson and Luke D. Vale and Russell David Petty},
  booktitle={Journal of gastrointestinal cancer},
  year={2012}
}
INTRODUCTION We conducted a systematic review of evidence on the effectiveness of imatinib at escalated doses of 600 mg/day or 800 mg/day for treatment of adults with unresectable or metastatic gastrointestinal stromal tumours (GIST), following progression on imatinib at the 400 mg/day dose, compared with sunitinib and/or 'best supportive care'. METHODS Electronic searches were undertaken to identify relevant randomised controlled trials (RCTs), non-randomised studies, and case series… CONTINUE READING
Highly Cited
This paper has 30 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

CRD’s guidance for undertaking systematic reviews in health care [document on the Internet

  • Systematic reviews
  • University of York: Centre for Reviews and…
  • 2012

Detailed analysis of survival and sfety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST

  • P Reichardt, Y Kang, W Ruka, B Seddon, A Guerriero, A Breazna
  • J Clin Oncol
  • 2008

Similar Papers

Loading similar papers…